• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
  • Issues
    • Current Issue
    • Issue Archives
  • Editor's Update
  • Advertise
  • Reprints
  • Authors
    • Author Instructions
    • Submission Portal
  • Reviewers
  • Contact

Search

Please register or login to continue using the site.

Controversial MS Treatment Lessens Fatigue, Research at ISET 2011 Shows

MIAMI BEACH, Fla.--(BUSINESS WIRE)--Multiple sclerosis (MS) patients may get some relief from severe fatigue from an experimental procedure to open blocked blood vessels in the chest and neck, suggests preliminary Stanford University research being presented at the 23rd annual International Symposium on Endovascular Therapy (ISET).

“If a person has MS and has a blood vessel obstruction, and if it’s removed, we will look at whether we can we demonstrate objectively that there is improvement in blood flow”

A year after doctors used either angioplasty or stents to open blocked veins of 30 MS patients, they suffered about half the fatigue, on average, than they had before the treatment, according to data being presented by Michael Dake, M.D., Thelma and Henry Doelger Professor in the Department of Cardiovascular Surgery at Stanford University School of Medicine in Stanford, Calif. Patients with the most common type of MS – relapsing-remitting – benefitted most.

Treatment for chronic cerebrospinal venous insufficiency (CCSVI) is controversial, with some doctors doubting the existence of the condition. Stanford and the Baptist Cardiac & Vascular Institute in Miami, plan to begin a trial in 2011 to assess the condition and treatment with angioplasty. “If a person has MS and has a blood vessel obstruction, and if it’s removed, we will look at whether we can we demonstrate objectively that there is improvement in blood flow,” Dr. Dake said.

The ISET meeting will feature several presentations on CCSVI. Among the featured speakers are Paolo Zamboni, M.D. of the University of Ferrara, Italy, a vascular surgeon who first proposed and is now testing the theory. Also speaking: patient advocates, skeptics, U.S. and Canadian doctors who provide the therapy, and James F. Benenati, M.D., president of the Society of Interventional Radiology.

About 400,000 Americans are affected by MS, which can be extremely debilitating, causing problems ranging from numbness and blurred vision to extreme fatigue and paralysis. The symptoms can come and go or become progressively worse.

Dr. Zamboni theorizes that abnormal blood flow can damage the nervous system and lead to MS. He reported initial results in 2009, suggesting the existence of CCSVI and that endovascular treatment relieved some MS symptoms and improved quality of life in certain MS patients. No U.S. studies have been published.

For more information, visit www.ISET.org.

Copies of ISET 2011 news releases are available online at www.ISETnews.org

image description image description


				

  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Tara Fields, Classified Sales Manager
    (800) 237-7285, ext. 259

vdm Blogs

Aneurysms and Cancer: Which comes first in the endovascular era?

Ross Milner MD FACS

What is the best therapy when we compare current data for revascularization of the SFA?

Lawrence A. Garcia MD

When a Patient Presents with an Ulcer, Take a Careful History

Richard R. Heuser MD FACC FACP FESC FSCAI

Long-term results with bare-metal LifeStent in the SFA: Is this bad news for DES technologies?

Frank J Criado MD FACS FSVM

Two-Year Restenosis Rates are Equal for CEA and CAS, and Quite Low

Frank J Criado MD FACS FSVM
more »

Vascular Newswire

  • Abbott's XIENCE PRIME and XIENCE V Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
    Wed, 05/16/12 - 9:26am
  • Hospital Mortality Rates for Cardiovascular Revascularization Patients Varies Significantly by State
    Tue, 05/15/12 - 9:31am
  • Boston Scientific Announces CE Mark and European Launch of Innova Self-expanding Bare-metal Stent System
    Mon, 05/14/12 - 12:07pm
  • Self-Expanding and Balloon-Expandable Stent Systems Perform Well in Study of Real-World Peripheral Artery Disease Patients
    Fri, 05/11/12 - 11:06am
more »

Clinical Events Calendar

  • EuroPCR 2012
    Tue, 05/15/2012 - Fri, 05/18/2012
    Paris, France
  • International Vein Congress (IVC) 2012
    Thu, 05/31/2012 - Sun, 06/03/2012
    Miami Beach, FL, United States
  • New Cardiovascular Horizons (NCVH)
    Wed, 06/06/2012 - Sat, 06/09/2012
    New Orleans, LA, United States
more »

Poll

The current focus to decrease the profile size of aortic stent-grafts: :
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2012 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2012 HMP Communications